查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951214

全基因組和EXOME定序市場－全球產業規模、佔有率、趨勢、機會和預測：按產品、工作流程、應用、最終用戶、地區和競爭格局分類，2021-2031年

Whole Genome and Exome Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Workflow, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球全基因組和EXOME定序市場預計將從 2025 年的 32.4 億美元大幅成長至 2031 年的 69.3 億美元，複合年成長率達 13.51%。

該市場涵蓋專門用於對生物體整個DNA序列或蛋白質編碼EXOME區域進行定序的技術和服務。其成長主要受高通量定序成本快速下降以及精準醫療迫切需求的推動，而精準醫療則需要廣泛的基因組分析以實現個人化治療。這些因素對於加速藥物研發和提高複雜遺傳疾病臨床診斷的準確性至關重要。根據個人化醫療聯盟預測，到2024年，個人化藥物將佔新核准治療性分子實體的約38%，凸顯了基因組數據在現代藥物研發中的重要性。

市場概覽
預測期 2027-2031
市場規模：2025年 32.4億美元
市場規模：2031年 69.3億美元
複合年成長率：2026-2031年 13.51%
成長最快的細分市場 測量設備
最大的市場 北美洲

然而，市場在管理和解讀這些定序方法產生的大量資料集方面面臨著許多挑戰。對龐大的運算儲存空間和專業生物資訊技能的需求，對許多醫療機構而言都是一個瓶頸。此外，關於資料隱私和病患基因記錄倫理管理的嚴格監管要求，也增加了跨國資料交換的複雜性，並可能限制全球合作研究的擴充性。

市場促進因素

定序成本和處理時間的顯著降低是市場擴張的關鍵驅動力，這主要得益於高通量系統的引入。這些技術進步使實驗室能夠以遠低於以往的成本分析海量基因組文庫，從而使全基因測序從專門的研究工具轉變為常規臨床實踐的一部分。這種營運模式的演變形成了一個良性循環：成本的降低推動了技術的普及，並促使製造商向診斷和研究中心提供先進的設備。例如，Illumina公司在2024年2月的財報中宣布，2023年全年共交付了352套NovaSeq X系統，顯示業界正朝著更有效率、更經濟的定序解決方案發展。

同時，政府主導的大規模基因組計畫和不斷成長的研究經費正顯著推動對定序服務的需求。各國正投入大量資源進行人群層面的研究，旨在闡明遺傳多樣性，支持醫療服務提供者的日常工作流程，並促進建構精準醫療所需的龐大參考資料資料庫。這一趨勢在推動舉措快速數位化的大型公共衛生計劃中尤其明顯。根據美國國立衛生研究院 (NIH) 於 2024 年 2 月宣布的「我們所有人研究計畫」(All of Us Research Program)，該計畫已發布 245,388 個臨床級全基因組序列資料集，旨在加速生物醫學研究。這種海量數據的產生也延伸到了製藥領域。 2024 年，再生元製藥公司 (Regeneron Pharmaceuticals) 宣布其基因中心已完成第 200 萬個EXOME序列測定，這充分展現了當前全球市場數據規模的驚人。

市場挑戰

定序技術所產生的大量資料集的處理和解讀難度極大，這成為全球全基因組和EXOME定序市場成長的主要障礙。高通量技術會產生Petabyte原始數據，而醫療機構往往會因為計算儲存不足和生物資訊專業知識匱乏而面臨嚴重的瓶頸。無法有效處理和分析這些基因組數據會延緩原始數據向臨床應用的轉化，增加營運成本並阻礙研究進展。因此，市場在擴展服務以滿足日益成長的精準醫療需求方面面臨著巨大挑戰，重要的遺傳資訊往往被困在孤立或整合度低的系統中。

數據管治凸顯了這種營運障礙，並且仍然是整個生命科學產業面臨的關鍵挑戰。根據皮斯托亞聯盟（Pistoia Alliance）的數據顯示，54%的生命科學專業人士認為非結構化資料是2024年面臨的主要挑戰，48%的人認為缺乏元資料標準化阻礙了高效的資料存取和利用。這些數據表明，基因組數據的龐大體量和複雜性直接限制了藥物研發和診斷技術進步的速度和效率，這限制了整個定序市場的成長前景。

市場趨勢

從短讀長定序到長讀長定調查方法的轉變調查方法改變市場模式。這項轉變的驅動力在於，人們需要辨識結構變異並繪製複雜區域圖譜，而這些區域往往被短讀長定序平台所忽略。長讀長定序技術在建構全面的參考基因組和闡明單倍型方面正變得日益重要，這顯著提高了罕見疾病診斷的準確性。高通量長讀長定序儀的商業性應用也推動了這項轉變。根據Pacific Biosciences公司2024年2月發布的財報，該公司在2023會計年度共出貨173套Revio定序系統，顯示業界正大力推進這些先進技術的應用。

同時，隨著全EXOME定序序 (WES) 被納入臨床腫瘤學，全面的腫瘤分析正逐漸成為標準流程。這項進展使腫瘤學家能夠利用EXOME的切片檢查來檢測可治療的突變，並比有限的標靶檢測更有效地追蹤治療抗藥性。 WES 可對體細胞突變進行全面分析，對於選擇合適的標靶治療和免疫療法至關重要。 Guardant Health 的報告顯示，2024 年 5 月，其臨床檢測量達到 46,900 例，比前一年成長 20%，這進一步印證了精準癌症治療對廣泛基因組數據的依賴性日益增強。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球全基因組與EXOME定序市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按產品（套件、設備）
    • 依工作流程（全基因測序(WGS)、全EXOME定序(WES)）
    • 依應用領域（腫瘤學、微生物學、非侵入性產前檢測 (NIPT)、其他）
    • 按最終用戶（製藥和生物技術公司、診斷實驗室、醫院和診所、研究和學術機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美全基因組與EXOME定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲全基因組與EXOME定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區全基因組與EXOME定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲全基因組和EXOME定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲全基因組與EXOME定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

13. 全球全基因組和EXOME定序市場：SWOT 分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Illumina
  • Thermo Fisher Scientific
  • BGI Genomics
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Agilent Technologies
  • QIAGEN
  • Roche
  • PerkinElmer
  • Macrogen

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 26562

The Global Whole Genome & Exome Sequencing Market is projected to expand significantly, rising from a valuation of USD 3.24 Billion in 2025 to USD 6.93 Billion by 2031, reflecting a compound annual growth rate of 13.51%. This market encompasses technologies and services dedicated to decoding the entire DNA sequence of an organism or its protein-coding exome segments. Growth is primarily underpinned by the rapid reduction in high-throughput sequencing costs and the urgent transition toward precision medicine, which demands extensive genomic profiling for individualized patient treatment. These elements are pivotal in expediting pharmaceutical research and enhancing the precision of clinical diagnostics for complex genetic disorders. According to the Personalized Medicine Coalition, it was reported in 2024 that personalized medicines represented roughly 38 percent of all newly authorized therapeutic molecular entities, underscoring the essential role of genomic data in contemporary drug development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.24 Billion
Market Size 2031USD 6.93 Billion
CAGR 2026-203113.51%
Fastest Growing SegmentInstruments
Largest MarketNorth America

Nevertheless, the market faces a substantial obstacle in the form of managing and interpreting the immense datasets produced by these sequencing methodologies. The need for extensive computational storage and specialized bioinformatics skills creates a bottleneck for numerous healthcare facilities. Furthermore, strict regulatory requirements concerning data privacy and the ethical management of patient genetic records add complexity to the cross-border exchange of data, potentially constraining the global scalability of collaborative research efforts.

Market Driver

The marked reduction in sequencing expenses and processing times serves as a major engine for market expansion, fueled largely by the deployment of high-throughput systems. These technological advancements enable laboratories to analyze immense genomic libraries at costs significantly lower than in the past, transitioning whole genome sequencing from a specialized research tool to a component of routine clinical practice. This operational evolution establishes a feedback cycle wherein reduced costs drive adoption, encouraging manufacturers to supply advanced instrumentation to diagnostic and research centers. For instance, Illumina reported in its February 2024 financial results that it shipped 352 NovaSeq X units throughout 2023, indicating a robust industry trend toward these more efficient and affordable sequencing solutions.

Simultaneously, the growth of large-scale government genomic programs and research funding is notably boosting the demand for sequencing services. Nations are committing substantial resources to population-level studies aimed at comprehending genetic diversity, which supports continuous workflows for providers and builds the extensive reference databases required for precision medicine. This drive is highlighted by major public health projects that are rapidly digitizing biobanks. According to the National Institutes of Health's February 2024 release regarding the 'All of Us Research Program', the initiative released a dataset comprising 245,388 clinical-grade whole genome sequences to speed up biomedical inquiry. This massive data generation extends to the pharmaceutical sector as well; Regeneron Pharmaceuticals announced in 2024 that its genetics center had sequenced its two millionth exome, demonstrating the colossal volume of data currently defining the global market.

Market Challenge

The intricacies involved in handling and interpreting the vast datasets produced by sequencing technologies represent a major barrier to the growth of the Global Whole Genome & Exome Sequencing Market. As high-throughput technologies yield petabytes of raw data, healthcare institutions often face critical bottlenecks caused by inadequate computational storage and a shortage of bioinformatics professionals. This incapacity to effectively process and analyze genomic data slows the conversion of raw sequences into practical clinical findings, raising operational expenses and hindering research progress. Consequently, the market encounters considerable difficulty in expanding its services to satisfy the rising demand for precision medicine, as essential genetic insights frequently remain locked within isolated or poorly integrated infrastructures.

Highlighting this operational obstacle, data governance persists as a significant issue throughout the life sciences industry. According to the Pistoia Alliance, in 2024, 54 percent of life science experts cited unstructured data as a primary difficulty, while 48 percent noted that the absence of metadata standardization restricts their ability to access and use data efficiently. These figures demonstrate how the immense volume and complexity of genomic data directly impede the speed and effectiveness of drug discovery and diagnostic advancement, thereby constraining the overall growth prospects of the sequencing market.

Market Trends

The shift from short-read to long-read sequencing methodologies is transforming the market, motivated by the necessity to identify structural variants and map complex regions that short-read platforms often overlook. Long-read technologies are becoming increasingly vital for constructing comprehensive reference genomes and resolving phased haplotypes, which significantly improves diagnostic precision for rare diseases. This transition is supported by the commercial uptake of high-throughput long-read instruments. According to Pacific Biosciences' financial results released in February 2024, the company shipped 173 Revio sequencing systems during the fiscal year 2023, indicating a strong industry trend toward adopting these sophisticated technologies.

At the same time, the incorporation of Whole Exome Sequencing (WES) into clinical oncology is becoming a standard practice for thorough tumor profiling. This development enables oncologists to use exome-based biopsies to detect actionable mutations and track treatment resistance more efficiently than limited targeted panels. WES offers a comprehensive examination of somatic changes, which is essential for choosing suitable targeted therapies and immunotherapies. As evidence of this growing reliance on extensive genomic data for precision cancer care, Guardant Health reported in May 2024 that its clinical test volumes reached 46,900, marking a 20 percent year-over-year increase.

Key Market Players

  • Illumina
  • Thermo Fisher Scientific
  • BGI Genomics
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Agilent Technologies
  • QIAGEN
  • Roche
  • PerkinElmer
  • Macrogen

Report Scope

In this report, the Global Whole Genome & Exome Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Whole Genome & Exome Sequencing Market, By Product

  • Kits
  • Instruments

Whole Genome & Exome Sequencing Market, By Workflow

  • Whole Genome Sequencing (WGS)
  • Whole Exome Sequencing (WES)

Whole Genome & Exome Sequencing Market, By Application

  • Oncology
  • Microbial
  • Non-Invasive Prenatal Testing (NIPT)
  • Others

Whole Genome & Exome Sequencing Market, By End User

  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Research and Academic Institutes
  • Others

Whole Genome & Exome Sequencing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Whole Genome & Exome Sequencing Market.

Available Customizations:

Global Whole Genome & Exome Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Whole Genome & Exome Sequencing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Kits, Instruments)
    • 5.2.2. By Workflow (Whole Genome Sequencing (WGS) Whole Exome Sequencing (WES))
    • 5.2.3. By Application (Oncology, Microbial, Non-Invasive Prenatal Testing (NIPT), Others)
    • 5.2.4. By End User (Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Hospitals and Clinics, Research and Academic Institutes, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Whole Genome & Exome Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Workflow
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Whole Genome & Exome Sequencing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Workflow
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Whole Genome & Exome Sequencing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Workflow
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Whole Genome & Exome Sequencing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Workflow
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Whole Genome & Exome Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Workflow
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Whole Genome & Exome Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Whole Genome & Exome Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Whole Genome & Exome Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Whole Genome & Exome Sequencing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Workflow
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Whole Genome & Exome Sequencing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Workflow
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Whole Genome & Exome Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Workflow
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Whole Genome & Exome Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Whole Genome & Exome Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Whole Genome & Exome Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Whole Genome & Exome Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Whole Genome & Exome Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Whole Genome & Exome Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Workflow
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Whole Genome & Exome Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Whole Genome & Exome Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Whole Genome & Exome Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America Whole Genome & Exome Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Workflow
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Whole Genome & Exome Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Whole Genome & Exome Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Whole Genome & Exome Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Whole Genome & Exome Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Illumina
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific
  • 15.3. BGI Genomics
  • 15.4. Oxford Nanopore Technologies
  • 15.5. Pacific Biosciences
  • 15.6. Agilent Technologies
  • 15.7. QIAGEN
  • 15.8. Roche
  • 15.9. PerkinElmer
  • 15.10. Macrogen

16. Strategic Recommendations

17. About Us & Disclaimer